A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International journal of pharmaceutics

• Publication date

  2017-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijpharm.2017.08.126PMID 28870765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circadian rhythms and influencing factors of xerostomia among Parkinson's disease patients.

  2018cited by this paper
• Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives

  2017cited by this paper
• Is Levodopa Pharmacokinetics in Patients with Parkinson’s Disease Depending on Gastric Emptying?

  2017cited by this paper
• Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson's disease who present with functional gastrointestinal symptoms

  2017cited by this paper
• Esophageal dysfunction in different stages of Parkinson's disease

  2017cited by this paper
• Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses

  2017cited by this paper
• Hyposalivation and xerostomia among Parkinson's disease patients and its impact on quality of life.

  2017cited by this paper
• Swallowing disorders in Parkinson's disease.

  2017cited by this paper
• A practical review of gastrointestinal manifestations in Parkinson's disease.

  2017cited by this paper
• Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson’s Disease: A Colon Transit and Volume Study

  2017cited by this paper
• Swallowing Disorders in Parkinson's Disease

  2017cited by this paper
• Utility of high-resolution anorectal manometry and wireless motility capsule in the evaluation of patients with Parkinson's disease and chronic constipation

  2016cited by this paper
• Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test.

  2016cited by this paper
• Novel Levodopa Formulations for Parkinson’s Disease

  2016cited by this paper
• Constipation: an emerging risk factor for Parkinson's disease?

  2016cited by this paper
• Imaging Systemic Dysfunction in Parkinson’s Disease

  2016cited by this paper
• Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models

  2016cited by this paper
• Quantitative Measures of Swallowing Deficits in Patients With Parkinson’s Disease

  2016cited by this paper
• Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state.

  2016cited by this paper
• Gastric emptying, postprandial blood pressure, glycaemia and splanchnic flow in Parkinson's disease.

  2016cited by this paper
• Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap(®) System.

  2015cited by this paper
• Similar in vitro drug release as a surrogate of therapeutic equivalence of locally acting gastrointestinal products--what is the right in vitro method?

  2015cited by this paper
• Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

  2015cited by this paper
• Characteristics of the saliva flow rates of minor salivary glands in healthy people.

  2015cited by this paper
• Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal

  2015cited by this paper
• Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies.

  2015cited by this paper
• Characterization of gastrointestinal disorders in patients with parkinsonian syndromes.

  2015cited by this paper
• Small intestine dysfunction in Parkinson’s disease

  2015cited by this paper
• The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease

  2015cited by this paper
• Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

  2015cited by this paper
• Constipation preceding Parkinson's disease: a systematic review and meta-analysis

  2015cited by this paper
• Characterisation of human saliva as a platform for oral dissolution medium development.

  2015cited by this paper
• The Relationship Between Limit of Dysphagia and Average Volume Per Swallow in Patients with Parkinson’s Disease

  2014cited by this paper
• Electrophysiological Evaluation of Oropharyngeal Dysphagia in Parkinson’s Disease

  2014cited by this paper
• Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors.

  2014cited by this paper
• Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.

  2014cited by this paper
• Beyond here be dragons: SIBO in Parkinson's disease

  2013cited by this paper
• The role of individual gastric emptying of pellets in the prediction of diclofenac in vivo dissolution.

  2013cited by this paper
• Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease

  2013cited by this paper
• Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms

  2013cited by this paper
• The role of small intestinal bacterial overgrowth in Parkinson's disease

  2013cited by this paper
• Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms

  2012cited by this paper
• Pathological correlates of gastrointestinal dysfunction in Parkinson's disease.

  2012cited by this paper
• Gastroparesis and Parkinson's disease: a systematic review.

  2012cited by this paper
• Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis.

  2012cited by this paper
• Swallowing in Patients with Parkinson’s Disease: A Surface Electromyography Study

  2012cited by this paper
• Dissolution testing of oral modified‐release dosage forms

  2012cited by this paper
• Postpyloric Gastrointestinal Peptides

  2012cited by this paper
• Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease.

  2012cited by this paper
• Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.

  2012cited by this paper
• Gastrointestinal dysfunction in Parkinson's disease.

  2011cited by this paper
• The importance of non-motor disturbances to quality of life in Parkinson's disease.

  2011cited by this paper
• Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild

  2011cited by this paper
• Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson’s disease? An analysis using the 13C-acetate breath test

  2011cited by this paper
• Gastrointestinal Symptoms in Parkinson Disease: Clinical Aspects and Management

  2011cited by this paper
• Reproductive factors and Parkinson's disease: A multicenter case–control study

  2011cited by this paper
• Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study)

  2011cited by this paper
• Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy

  2011cited by this paper
• Electrogastrographyc activity in Parkinson's disease patients with and without motor fluctuations

  2011cited by this paper
• Study of an integrated non-motor symptoms questionnaire for Parkinson's disease.

  2010cited by this paper
• Gastrointestinal dysfunction in Parkinson's Disease.

  2010cited by this paper
• Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease

  2010cited by this paper
• Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

  2010cited by this paper
• Reports Real-time Visualization of Altered Gastric Motility by Magnetic Resonance Imaging in Patients with Parkinson ’ s Disease

  2010cited by this paper
• The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease

  2010cited by this paper
• Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.

  2009cited by this paper
• The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

  2009cited by this paper
• Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.

  2009cited by this paper
• Major nutritional issues in the management of Parkinson's disease

  2009cited by this paper
• Evaluation of gastric emptying in familial and sporadic Parkinson disease.

  2009cited by this paper
• Wireless Capsule Motility: Comparison of the SmartPill® GI Monitoring System with Scintigraphy for Measuring Whole Gut Transit

  2009cited by this paper
• Is there a difference in gastric emptying between Parkinson’s disease patients under long-term l-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test

  2009cited by this paper
• Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy

  2009cited by this paper
• A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations.

  2009cited by this paper
• Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update

  2008cited by this paper
• Gastric emptying of a non‐digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy

  2008cited by this paper
• Anatomy and physiology of feeding and swallowing: normal and abnormal.

  2008cited by this paper
• Irregular gastrointestinal drug absorption in Parkinson's disease

  2008cited by this paper
• A Pilot Study of Respiration and Swallowing Integration in Parkinson’s Disease: “On” and “Off” Levodopa

  2008cited by this paper
• Use of the BioDis to generate a physiologically relevant IVIVC.

  2008cited by this paper
• Swallowing problems in Parkinson disease: frequency and clinical correlates

  2008cited by this paper
• Pharmacotherapy for Parkinson's Disease

  2007cited by this paper
• Optimizing bioavailability in the treatment of Parkinson's disease.

  2007cited by this paper
• Patient-reported autonomic symptoms in Parkinson disease

  2007cited by this paper
• Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients

  2007cited by this paper
• Sialorrhea in Parkinson's disease: A review

  2007cited by this paper
• Predictors of gastric emptying in Parkinson's disease

  2006cited by this paper
• CHAPTER 5 – Postpyloric Gastrointestinal Peptides

  2006cited by this paper
• Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients

  2006cited by this paper
• Quantitative study of salivary secretion in Parkinson's disease

  2006cited by this paper
• Non-motor symptoms of Parkinson's disease: diagnosis and management.

  2006cited by this paper
• Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test.

  2005cited by this paper
• Site‐specific delivery of anti‐inflammatory drugs in the gastrointestinal tract: an in‐vitro release model

  2005cited by this paper
• Prevalence and incidence of Parkinson's disease in Europe.

  2005cited by this paper
• Utility of Electrogastrography in Differentiating Parkinson’s Disease with or without Gastrointestinal Symptoms: A Prospective Controlled Study

  2005cited by this paper
• Formulation strategies for absorption windows.

  2005cited by this paper
• Electrogastrography in Patients with Parkinson’s Disease

  2005cited by this paper
• Salivary production in Parkinson's disease

  2005cited by this paper
• Swallowing abnormalities and dyskinesia in Parkinson's disease

  2005cited by this paper
• Surface Electromyography of Continuous Drinking in Healthy Adults

  2005cited by this paper

• Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease

  2023cites this paper
• Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation.

  2023cites this paper
• Carboxymethyl chitosan dopamine conjugates: Synthesis and evaluation for intranasal anti Parkinson therapy.

  2023cites this paper
• Potential and Challenges in Application of Physiologically Based Pharmacokinetic Modeling in Predicting Diarrheal Disease Impact on Oral Drug Pharmacokinetics.

  2023cites this paper
• Characterization of Aspirated Duodenal Fluids from Parkinson’s Disease Patients

  2023cites this paper
• Mechanisms of peripheral levodopa resistance in Parkinson’s disease

  2022cites this paper
• Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model

  2022cites this paper
• Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson's disease patients.

  2022cites this paper
• Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network.

  2021cites this paper
• Nose-to-brain delivery: a comparative study between carboxymethyl chitosan based conjugates of dopamine.

  2021cites this paper
• Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: a comparative study.

  2021cites this paper
• Impact of gastrointestinal physiology on drug absorption in special populations - An UNGAP review.

  2020influential citation
• An intact C-terminal end of albumin is required for its long half-life in humans

  2020influential citation
• Therapy for the Individual: Towards Patient Integration into the Manufacturing and Provision of Pharmaceuticals.

  2020cites this paper
• Altered Gut Microbiota and Intestinal Permeability in Parkinson's disease: Pathological highlight to Management.

  2019cites this paper
• Individualized in vitro and in silico methods for predicting in vivo performance of enteric‐coated tablets containing a narrow therapeutic index drug

  2019cites this paper
• Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson’s Disease

  2018cites this paper